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Vortioxetine (Lu AA21004) is an investigational novel antidepressant with multimodal activity that
functions as a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A
receptor agonist and inhibitor of the 5-HT transporter in vitro. Here we explore its anxiolytic and anti-
depressant potential in adult mice. Vortioxetine was assessed in BalB/cJ@RJ mice using the open-ﬁeld
and forced-swim tests (acute: p.o. 1 h, repeated: daily p.o. 21 days), and in 129S6/SvEvTac mice using
the novelty suppressed feeding paradigm (acute: p.o. 1 h, sustained: daily p.o. 14 or 21 days). Fluoxetine
and diazepam were controls. Acute and repeated dosing of vortioxetine produced more pronounced
anxiolytic- and antidepressant-like activities than ﬂuoxetine. Vortioxetine signiﬁcantly increased cell
proliferation and cell survival and stimulated maturation of immature granule cells in the subgranular
zone of the dentate gyrus of the hippocampus after 21 days of treatment. After 14 days, a high dose of
vortioxetine increased dendritic length and the number of dendrite intersections, suggesting that vor-
tioxetine accelerates the maturation of immature neurons. Vortioxetine displays an antidepressant and
anxiolytic proﬁle following repeated administration associated with increased neurogenesis at several
stages. Vortioxetine effects were observed at low levels of 5-HT transporter occupancy, suggesting an
alternative mechanism of action to 5-HT reuptake inhibition.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction pharmacotherapy can vary from 30 to 60% depending on theDepression is a major psychiatric disease, with az17% lifetime
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wasz37% (Guilloux et al., 2012; Rush et al., 2006). Side effects with
Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly re-
ported during chronic treatment, notably insomnia, somnolence,
dizziness, akathisia, and long-term sexual dysfunction (e.g.,
decreased libido, delayed ejaculation) (Hamon and Bourgoin,
2006). The modest efﬁcacy of conventional antidepressants such
as the selective serotonin (5-HT) reuptake inhibitors (SSRIs) calls
for novel approaches to treat depression and anxiety disorders.
Combinatorial pharmacological therapies, such as additional
blockade of aminergic receptors in addition to monoamine trans-
porter inhibition, have earlier been proposed to shorten the time to
antidepressant effect and/or to increase efﬁcacy in clinical studies
(Artigas et al., 2006; Kennedy et al., 2011).
The 5-HT1A and the 5-HT1B receptors were the ﬁrst serotonergic
receptors targeted to treat anxiety and depression due to their license. 
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modulate serotonergic neurotransmission (Gingrich and Hen,
2001; Guilloux et al., 2011). For instance, pindolol, a beta adreno-
ceptor blocker with 5-HT1A receptor partial agonism, has shown
some efﬁcacy in augmentation strategies with SSRIs; however, the
low doses used in clinical studies, its antagonistic action on 5-HT1B
heteroreceptors combined with its effects on post-synaptic 5-HT1A
receptors limits its efﬁcacy (Guilloux et al., 2006;Whale et al., 2010;
Martiny et al., 2012).
A link between the activity of antidepressant drugs and 5-HT3
receptor function has been suggested since 5-HT3 receptor antag-
onists administered alone exert antidepressant- and anxiolytic-like
effects in preclinical settings (Costall and Naylor, 2004). Moreover,
pretreatment with the 5-HT3 receptor antagonist ondansetron
potentiates the effects of antidepressant drugs in preclinical models
(Redrobe and Bourin, 1997; Ramamoorthy et al., 2008). However,
the preclinical observations were not conﬁrmed in the few clinical
studies that have been conducted. Thus, there is currently a weak
support of 5-HT3 antagonism alone or in combination with SSRI in
the treatment of depression. Furthermore, whereas selective 5-HT3
receptor antagonists are used routinely to attenuate nausea asso-
ciated with chemotherapy, irradiation or cisplatin treatment, there
are only few studies conducted showing that 5-HT3 receptor
antagonism reduces nausea in patients being treated with SSRIs
(Bailey et al., 1995).
Early indications of an involvement of 5-HT7 receptors in mood
disorders came from a study showing down-regulation of 5-HT7
receptor expression after chronic treatment with various antide-
pressants (Mullins et al., 1999; for a review, see Mnie-Filali et al.,
2011). Recent studies further support a role for 5-HT7 receptors in
treating depression. Hence, SB-269970, a 5-HT7 receptor antago-
nist, decreased immobility in both the tail suspension and forced
swim tests (Guscott et al., 2005; Hedlund et al., 2005; Faure et al.,
2006; Wesolowska et al., 2006a, 2006b) and enhanced the
antidepressant-like effect of citalopram (Bonaventure et al., 2007;
Sarkisyan et al., 2010). In agreement with these pharmacological
data, 5-HT7 receptor knockout mice showed reduced immobility in
both the forced swim and the tail suspension tests (Hedlund et al.,
2005). Thus, it appears that the efﬁcacy of SSRIs may be enhanced
by blocking feedback systems and modulating relevant receptors.
Vortioxetine (Lu AA21004; 1-[2-(2,4-dimethyl-phenylsulfanyl)-
phenyl]-piperazine) is a novel investigational antidepressant with
multimodal activity. Vortioxetine acts as an inhibitor at the 5-HT
transporter (SERT, Ki ¼ 1.6 nM) in recombinant cells expressing
human receptors or SERT and as a 5-HT3, 5-HT7 and 5-HT1D re-
ceptor antagonist (Ki ¼ 3.7, 19 and 54 nM, respectively), a partial
agonist at the 5-HT1B receptor (Ki ¼ 33 nM), an agonist at the 5-
HT1A receptor (Ki ¼ 15 nM) (Bang-Andersen et al., 2011; Mork
et al., 2012; Westrich et al., 2012). In rats the binding afﬁnities
are Ki ¼ 1.1, 200, 3.7, 16 and 230 nM, for 5-HT3, 5-HT7, 5-HT1D, 5-
HT1B, and 5-HT1A receptors, respectively and Ki ¼ 8.6 nM for the
SERT (Mork et al., 2012; Westrich et al., 2012). In vivo, vortioxetine
increases the extracellular levels of 5-HT, noradrenaline (NA), and
dopamine (DA) in rat prefrontal cortex and hippocampus (Mork
et al., 2012).
Although preclinical ﬁndings indicate that, acutely, vortioxetine
produces an antidepressant and anxiolytic proﬁle (Mork et al.,
2012), the behavioural consequences of chronic administration
have not been described. To investigate the effects of chronic vor-
tioxetine treatment, as well as to conﬁrm its anxiolytic- and
antidepressant-like activities, we assessed its behavioural effects
after acute (1 h) or repeated (14 or 21 days) dosing using the open
ﬁeld (OF) paradigm, the novelty suppressed feeding (NSF) para-
digm and the mouse forced swim test (FST). OF and FST studies
were conducted in Balb/cJ mice that have been shown to display ahigh basal anxiety- and depression-like behaviour (Belzung and
Griebel, 2001). We conﬁrmed the behavioural effects of 14 or 21
days of treatment with vortioxetine in 129S6/SvEvTac mice in the
NSF paradigm. As stimulation of hippocampal neurogenesis has
been suggested to underlie the delayed onset of therapeutic efﬁ-
cacy of SSRIs and tricyclic antidepressants (Duman et al., 1999;
Malberg et al., 2000; Santarelli et al., 2003), we investigated the
effects of vortioxetine dosed for 14 or 21 days on cell proliferation
and maturation/survival in the dentate gyrus in 129S6/SvEvTac
mice.2. Methods
2.1. Animals
One hundred and eighty BALB/cJ@Rj male mice, 7e8 weeks old (25e30 g, Centre
d’élevage Janvier, Le Genest-St-Isle, France) were used for the acute and repeated
dosing experiments in the OF and FST. Eighty 129S6/SvEvTac male mice, 7e8 weeks
old (25e30 g, Taconic Farms, Denmark) were used for the acute and repeated dosing
NSF and the cell proliferation and survival/maturation study and Sholl analysis.
Mice were maintained under standard conditions (12/12 h light/dark cycle,
lights on at 6AM, 22  1 C, food and water ad libitum, 5 mice/cage). The protocols
involving animals and their care were conducted in conformity with the institu-
tional guidelines that are in compliance with national and international laws and
policies (Council directive # 87-848, October 19, 1987, Ministère de l’Agriculture et
de la Forêt, Service Vétérinaire de la Santé et de la Protection Animale, permissions #
92-256B to DJD).2.2. Drugs and treatment
2.2.1. Acute studies
Three doses of vortioxetine (2.5, 5 and 10 mg/kg, free base dissolved in 10% b-
cyclodextrin, oral gavage, p.o.,) were used in the OF test, the NSF test and the FST. The
effects of vortioxetine were compared to the vehicle control group (10% b-cyclo-
dextrin) and also to a ﬂuoxetine- (18 mg/kg p.o., (David et al., 2007)) and a
diazepam-treated group (1.5 mg/kg, s.c. (David et al., 2007)). All doses were cor-
rected for theweight of the salt. All treatments were administered 1 h before testing.
2.2.2. Chronic studies
Two doses of vortioxetine (5 and 20 mg/kg/day, free base dissolved in 10% b-
cyclodextrin, oral gavage, p.o.) were tested in mice after 14 days of administration in
the NSF and 21 days of administration in the OF test, the NSF test and the FST. The
mice were tested 24 h after the last dose. The effects of vortioxetine were compared
to a vehicle control group (10% b-cyclodextrin) and also to a ﬂuoxetine-treated group
(18 mg/kg/day p.o.).2.3. Ex vivo SERT and 5-HT3 receptor occupancy assays
Brains frommice treated with vehicle, ﬂuoxetine, or vortioxetine (1 h after acute
administration or 24 h after the 14th or 21st injection) were ﬂash frozen, sectioned
coronally using a cryostat, and then mounted on slides and frozen until use. Slices
were 20 mm thick, and began at approximately þ1.2 mm anterior from bregma for
SERT receptor occupancy or 2.7 mm posterior from bregma for 5-HT3 receptor
occupancy determination (Franklin and Paxinos, 2008). Slides were stored for at
least 24 h at 20 C before use in autoradiography experiments.
2.3.1. Assessment of SERT occupancy
Slides were incubated at room temperature for 60 min in buffer (50 mM Trise
HCl, 150 mM NaCl, 5 mM KCl, pH ¼ 7.4) containing 4.5 nM [3H]-escitalopram.
Nonspeciﬁc binding was determined using 1 mM escitalopram. Slides were washed
brieﬂy in cold buffer, dried, and exposed in a Beta imager for 16 h. The region of
interest (ROI) for the SERT assay included the lateral andmedial septum, the nucleus
accumbens and the olfactory tubercle. An example image of the ROI for the SERT
assay can be found in Supplementary Fig. 2A.
2.3.2. Assessment of 5-HT3 receptor occupancy
Slides were preincubated for 5 min in a buffer consisting of 50 mM Tris and
150 mM NaCl. Slides were dried under a stream of air for 30e45 min. Subsequently,
slides were incubated at room temperature for 60 min in buffer (50 mM TriseHCl,
150 mM NaCl, 5 mM KCl, pH ¼ 7.4) containing 1 nM [3H]LY278584 (Perkin-Elmer,
USA). Nonspeciﬁc binding was determined using 1 mM ondansetron. Slides were
washed brieﬂy in cold buffer, dried, and exposed in a Beta imager for 24 h. The ROI
for the 5-HT3 receptor occupancy assay consisted of the hippocampus. An example
image for the 5-HT3 receptor occupancy assay can be found in Supplementary
Fig. 2B.
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2.4.1. The open-ﬁeld paradigm
Motor activity was quantiﬁed in Plexiglas OF boxes 43  43 cm (MED associates,
Georgia, VT, USA) during a 10 min session (Popa et al., 2010). Two sets of 16 pulse-
modulated infrared photobeams were placed on opposite walls 2.5 cm apart to re-
cord xey ambulatory movements. Activity chambers were computer interfaced for
data sampling at 100 ms resolution. The centre was deﬁned as a 32  32 cm central
arena. Dependent measures were: total time spent in the centre, the numbers of
entries into the centre and distance travelled in the centre divided by total distance
travelled. Overall motor activity was quantiﬁed as the total distance travelled (cm).
2.4.2. The novelty-suppressed feeding test
The NSF paradigm is a conﬂict test that elicits competing motivations: it does
not only measure anxiety components of behaviour, but also measures the animal’s
motivation to eat the pellet. This implies that the NSF differs from anxiety-related
tests such as the open ﬁeld or the elevated plus maze paradigms. Brieﬂy, animals
were food-deprived for 24 h prior to the test. Testing was performed in a
50 50 20 cm box coveredwith bedding and illuminated by a 70W lamp. The NSF
test was carried out during a 5 min period as described by Santarelli et al. (2003). At
the time of testing, a single pellet of food (regular chow)was placed on awhite paper
platform positioned in the centre of the box. Mice were tested individually after
placing them in the corner of the box for 10 min. The latency to eating was timed.
Immediately afterwards, the animal was transferred to its home cage and the
amount of food consumed during the subsequent 5 min was measured, serving as a
control for change in appetite as a possible confounding factor (home cage food
consumption), because antidepressants are known to affect appetite.
2.4.3. The mouse forced swim test
The FST procedurewasmodiﬁed to enhance the sensitivity to detect the putative
antidepressant-like activity of drugs (Rainer et al., 2012; Porsolt et al., 1977). Brieﬂy,
mice were placed into clear plastic buckets, 20 cm in diameter and 23 cm deep, ﬁlled
up to two-thirds with water at z24 C. Automated scoring was done using the
automated X’PERT FST (Bioseb, Vitrolles, France). Dependent variables were
mobility, swimming and climbing duration.
2.5. Immunohistochemistry
2.5.1. 5-Bromo-2-deoxyuridine (BrdU) labelling
2.5.1.1. Proliferation study. Mice were administered BrdU (150 mg/kg i.p.) 2 h before
sacriﬁce and processed as described in David et al. (2009). BrdU-positive (BrdUþ)
cells were counted using a BX51 microscope (Olympus, Germany).
2.5.1.2. Survival study. Mice were administered BrdU (150 mg/kg, i.p. b.i.d. for 3
days) 4 weeks before sacriﬁce. We then proceeded as described by Xia et al. (2012).
BrdUþ cells were counted under the microscope.
2.5.2. Doublecortin (DCX) labelling for maturation index study
The immunohistochemistry protocol was adapted from David et al. (2009). DCX-
positive (DCXþ) cells were subcategorized according to their dendritic morphology:
DCXþ cells and DCXþ cells with tertiary (or higher order) dendrites. The maturation
index was deﬁned as the ratio of DCXþ cells possessing tertiary dendrites to the total
number of DCXþ cells.
2.6. Sholl analysis
For Sholl analysis, DCXþ cells with tertiary, relatively untruncated dendritic
branches were traced for each 35 mm hippocampal slice using Neurolucida software
(MicroBrightField, Williston, VT) on an Olympus BX51 microscope equipped with a
motorized stage device and 100 immersion oil objective. DCX immunohisto-
chemistry was done to maximize the labelling of dendrites. Sholl analysis for den-
dritic complexity was performed using the accompanying software (NeuroExplorer;
MicroBrightField, version 10), calculating dendritic complexity including dendritic
length and number of intersections (branch points).
2.7. Statistical analysis
For all experiments except the NSF, a one-way ANOVA was performed and re-
sults were expressed as mean  SEM values. When main effects were signiﬁcant,
treatment comparisons were analysed using either PLSD (behaviour) or Tukey’s
post-hoc test. Unpaired t-test analysis was also used for planned comparisons. In the
NSF test, a KaplaneMeier survival analysis was applied due to the non-normal
distribution of data, as described by Samuels and Hen (2012). Animals that did
not eat during the 10-min test period were statistically censored. The ManteleCox
log-rank test was used to evaluate differences between experimental groups.
Complete description of statistics can be found in the Supplementals
(Supplementary Table 1). Linear correlation analyses of latency values in the NSF vs.
number DCXþ cells with tertiary dendrites were performed using the Pearson
correlation coefﬁcient “R”.For ex vivo autoradiography experiments, surface radioactivity (expressed as
cpm/mm2) was measured using Beta visionþ software version 2.0 (Biospace Lab,
Paris, France). Radioactivity was quantiﬁed from a ROI deﬁned a priori on the basis of
receptor mapping experiments performed by this laboratory. This region remained
consistent across each slice of tissue within a given assay. Speciﬁc binding was
determined by subtracting nonspeciﬁc binding from total binding. Speciﬁc binding
for each brain was normalized to the average speciﬁc-bound radioactivity from
vehicle-treated individuals and expressed as a percentage of vehicle binding. These
percentages were subtracted from 100% to obtain percent receptor occupancy.
Differences were considered signiﬁcant when p  0.05. All analyses were con-
ducted using Statview 5.0 for IBM-compatible computers.3. Results
3.1. SERT and 5-HT3 receptor occupancy after acute and chronic
treatment with vortioxetine in BALB/cJ and 129Sv mice
Acute dosing of vortioxetine (5 mg/kg and 10 mg/kg, p.o., 1 h)
resulted in 60e70% occupancy of the SERT for both strains at the
time of behavioural testing (Table 1). This was signiﬁcantly lower
than the approximately 90% SERT occupancy with ﬂuoxetine
(p < 0.01 and p < 0.05, compared to vortioxetine 5 and 10 mg/kg,
respectively). Conversely, the same doses of vortioxetine resulted in
>90% occupancy of the 5-HT3 receptors, while no detectable oc-
cupancy was observed after ﬂuoxetine administration (Table 2).
After chronic (daily for 14 or 21 days) administration of vorti-
oxetine (5 or 20 mg/kg), practically no occupancy of the SERT was
measurable at the time of behavioural and neurogenic assessment,
i.e., 24 h after the last dose in both strains, whereas ﬂuoxetine
occupied >90% of the SERT at that time point (Table 1). Chronic
dosing of vortioxetine, except in the high-dose BALB/cJ group,
resulted in low non-signiﬁcant occupancy of 5-HT3 receptors
(Table 2).3.2. Vortioxetine produces acute antidepressant and anxiolytic
activity in BALB/cJ and 129Sv mice
In the OF test in BALB/cJ mice (Fig. 1AeD), vortioxetine 2.5 and
5 mg/kg induced an anxiolytic-like effect similar to that of diaz-
epam (1 mg/kg), characterized by an increase in the time spent in
the centre (Fig. 1A: F5,62 ¼ 2.7, p < 0.05; p < 0.05 for vortioxetine
2.5 mg/kg, p ¼ 0.053 for vortioxetine 5 mg/kg; p < 0.01 for diaz-
epam). Vortioxetine and diazepam also increased the number of
entries (Fig. 1B p < 0.05 for vortioxetine 2.5 mg/kg or diazepam,
unpaired t-test planned comparison) and the distance travelled in
the centre (Fig. 1C p < 0.01 for diazepam; p < 0.05 for vortioxetine
2.5 and 5mg/kg, unpaired t-test planned comparison). Vortioxetine
at a higher dose (10 mg/kg) as well as ﬂuoxetine had no signiﬁcant
effect on any of the measured parameters. Distance travelled in the
periphery (Fig. 1D), an index of locomotion in a non-stressful
environment, was unchanged for all treatments. Similarly, no ef-
fect of treatment was observed on overall locomotor activity
(Supplementary Fig. 3).
In the FST in BALB/cJ mice (Fig. 1EeG), vortioxetine (5 mg/kg)
signiﬁcantly increased the mobility duration (Fig. 1E p < 0.01, un-
paired t-test planned comparison), and signiﬁcantly increased
swimming (Fig. 1F p < 0.01, unpaired t-test planned comparison)
and climbing behaviour (Fig. 1G p < 0.05, unpaired t-test planned
comparison). Comparatively, ﬂuoxetine also increased mobility
(Fig. 1E p < 0.01, unpaired t-test planned comparison), apparently
through an increase of swimming duration only (Fig. 1F p < 0.05,
unpaired t-test planned comparison).
The 5- but not the 10-mg/kg dose of vortioxetine had an
antidepressant/anxiolytic-like effect in the NSF test in 129Sv mice
similar to that of diazepam (Fig. 2B: F5,54¼ 7.3, p< 0.0001; p< 0.01
for diazepam or vortioxetine at 5 mg/kg). In contrast, ﬂuoxetine
Table 1
Serotonin transporter occupancy in 129S6/SvEvTac and BALB/cJ mice after acute and chronic treatment. Serotonin transporter occupancy of vortioxetine and ﬂuoxetine after
acute (p.o., 1 h) or chronic (daily p.o. administration for 14 and 21 days and measurement 24 h after the last dose) in 129/SvEvTac and Balb/cJ mice. Data (n ¼ 3e4 animals/
group) are expressed in percentage of occupancy (mean  SEM) and speciﬁc binding values in cpm/mm2 (mean  SEM).
Strain Treatment Duration
Acute 14 days 21 days
Occupancy (%) Speciﬁc bound
(cpm/mm2)
Occupancy (%) Speciﬁc bound
(cpm/mm2)
Occupancy (%) Speciﬁc bound
(cpm/mm2)
129S6/SvEvTac Vehicle 0  4.0 11  0.4 0  5.9 9.7  0.6 0  5.4 10  0.6
Fluoxetine 91  1.7*** 1  0.2*** ND ND 98  0.3*** 0.13  0.03***
Vortioxetine 5 mg/kg/d 70  2.9***,## 3.2  0.3***,## 14  10 8.4  1 5.9  2.2### 9.6  0.2###
20 mg/kg/d ND ND 1.1  0.6 9.8  0.1 0.4  2.9### 10  0.3###
BALB/cJ Vehicle 0  7.9 7.1  0.6 ND ND 0  3.1 7.7  0.2
Fluoxetine 93  1.6*** 0.5  0.1*** ND ND 92  0.4*** 0.6  0.03***
Vortioxetine 5 mg/kg/d 63  0.9***,## 2.6  0.1***,## ND ND 0.6  7.0### 7.6  0.5###
10 mg/kg/d 69  3.4***,# 2.17  0.2***,# ND ND ND ND
20 mg/kg/d ND ND ND ND 5.9  4.1### 8.1  0.3###
***p < 0.0001, **p < 0.01 and *p < 0.05 when compared to the vehicle group, within strain and duration of treatment.
###p < 0.0001, ##p < 0.01 and #p < 0.05 when compared to the ﬂuoxetine group, within strain and duration of treatment.
ND: not determined.
Detailed statistical results are shown in Supplementary Table 1.
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and tended to increase latency (p ¼ 0.057). The results of the one-
way ANOVA were conﬁrmed by a KaplaneMeier survival analysis
followed by a ManteleCox log-rank test (Fig. 2A, p < 0.01 for
diazepam and vortioxetine 5 mg/kg). Food consumption in the
home cage was monitored after the behavioural test and displayed
no differences between groups (F5,54¼1.2, p¼ 0.34, Supplementary
Fig. 4).
3.3. Chronic vortioxetine produced sustained antidepressant and
anxiolytic activity in BALB/cJ and 129Sv mice
In BALB/cJ mice, chronic (21 days) administration of vortiox-
etine, 5 mg/kg per day and test 24 h after the last dose, resulted in
an anxiolytic-like activity in the OF test characterized by increased
time spent in the centre (Fig. 3A: F3,48 ¼ 3.1, p < 0.05; p < 0.01 for
vortioxetine 5 mg/kg), and increased number of entries (Fig. 3B
p < 0.05 for vortioxetine 5 mg/kg, unpaired t-test planned com-
parison). Neither vortioxetine 20 mg/kg per day and test 24 h after
the last dose or ﬂuoxetine administration had a signiﬁcant effect on
the number of entries, the time spent in the centre or distance
travelled. Distance travelled in the centre or in the periphery wasTable 2
5-HT3 receptor occupancy in 129S6/SvEvTac and BALB/cJ mice after acute and chronic trea
or chronic (daily p.o. administration for 14 and 21 days andmeasurement 24 h after the las
percentage of occupancy (mean  SEM) and speciﬁc binding values in cpm/mm2 (mean
Strain Treatment Duration
Acute
Occupancy (%) Speciﬁc bound
(cpm/mm2)
129S6/SvEvTac Vehicle 0  4.2 0.09  0.004
Fluoxetine 6.3  9.4 0.1  0.01
Vortioxetine 5 mg/kg/d 94  0.4***,### 0.005  0.0004
20 mg/kg/d ND ND
BALB/cJ Vehicle 0  7.6 0.22  0.02
Fluoxetine 3.4  9.2 0.21  0.02
Vortioxetine 5 mg/kg/d 92  1.5***,### 0.016  0.003**
10 mg/kg/d 97  1.0***,### 0.005  0.002**
20 mg/kg/d ND ND
***p < 0.0001, **p < 0.01 and *p < 0.05 when compared to the vehicle group, within str
###p < 0.0001, ##p < 0.01 and #p < 0.05 when compared to the ﬂuoxetine group, withi
ND: not determined.
Detailed statistical results are shown in Supplementary Table 1.unchanged in all treatment groups (Fig. 3CeD). Similarly, no effect
of treatment was observed on overall locomotor activity
(Supplementary Fig. 5).
In the FST in BALB/cJ mice (Fig. 3EeG), chronic (21 days) vorti-
oxetine, 5 mg/kg per day, but not 20 mg/kg per day, signiﬁcantly
increased the mobility duration (Fig. 3E: F3,42 ¼ 4.6, p < 0.01;
p < 0.01 for vortioxetine 5 mg/kg). As in the acute study, the in-
crease was due to a combination of increased duration of swim-
ming (Fig. 3F: F3,42 ¼ 4.0, p < 0.05; p < 0.01 for vortioxetine 5 mg/
kg) and climbing behaviour (Fig. 3G p < 0.05 for vortioxetine 5 mg/
kg, unpaired t-test, planned comparison). Fluoxetine had no sig-
niﬁcant effect on any of the parameters measured in this test
(p ¼ 0.69, p ¼ 0.49 and p ¼ 0.89, for mobility, swimming and
climbing, respectively).
Vortioxetine, 20 mg/kg per day and test 24 h after last dose,
administered for 14 but not 21 days, induced a signiﬁcant
reduction in the latency to feed in the NSF test in 129Sv mice (14
days: Fig. 4A: p < 0.01 KaplaneMeier survival analysis followed
by a ManteleCox log-rank test, conﬁrmed at the trend level
(p ¼ 0.067) by one-way ANOVA in Fig. 4B. 21 days: p ¼ 0.37,
Fig. 4D). At a lower dose (5 mg/kg per day) and test 24 h after the
last dose, vortioxetine reduced the latency to feed after 21 days oftment. 5-HT3 receptor occupancy of vortioxetine and ﬂuoxetine after acute (p.o., 1 h)
t dose) in 129/SvEvTac and Balb/cJ ice. Data (n¼ 3e4 animals/group) are expressed in
 SEM).
14 days 21 days
Occupancy (%) Speciﬁc bound
(cpm/mm2)
Occupancy (%) Speciﬁc bound
(cpm/mm2)
0  6.8 0.1  0.01 0  11 0.11  0.01
ND ND 8  9.3 0.097  0.01
***,### 3  13 0.1  0.01 13  10 0.092  0.01
8.2  8.4# 0.96  0.01# 19  9.8 0.085  0.01
ND ND 0  2.8 0.19  0.01
ND ND 12  3.2 0.16  0.01
*,### ND ND 7  5.3 0.20  0.01
*,### ND ND ND ND
ND ND 42  15* 0.11  0.03*
ain and duration of treatment.
n strain and duration of treatment.
Open Field
D
is
ta
nc
e 
in
 p
er
ip
he
ry
 (in
 cm
)
500
1000
1500
2000
0
D
is
ta
nc
e 
in
 c
en
te
r (
in 
cm
)
**
* *
100
200
300
400
0
En
tri
es
 in
 c
en
te
r * *
0
40
60
80
100
20
**
*
*
Ti
m
e 
in
 th
e 
ce
nt
er
 (in
 se
c.)
0
40
60
80
20
A
B
C
D
Cl
im
bi
ng
 d
ur
at
io
n 
(se
c.) *
2
4
6
8
10
0
Sw
im
m
in
g 
du
ra
tio
n 
(se
c.)
20
40
60
80
100
0
*
**
M
ob
ilit
y 
(se
c.)
50
0
100
150
**
*
Forced Swimming Test
E
F
G
Treatments
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Fig. 1. Effects of acute vortioxetine treatment in the open ﬁeld paradigm and the forced swim test in BALB/cJ@Rj mice. Behavioural effects of vortioxetine were studied after 1-
h administration at doses of 2.5, 5 and 10 mg/kg, compared to those of vehicle, diazepam (1.5 mg/kg) and/or ﬂuoxetine (10 mg/kg) in the open-ﬁeld paradigm and the mouse
forced swim test. Data are expressed as mean  SEM. Anxiety was expressed as total of the time spent in the centre (A) and the number of entries in the centre (B) for the entire
session. Locomotor activity was reported as total ambulatory distance travelled in the centre (C) and in the periphery (D) for the entire session. In the FST, mobility (E), swimming
(F) and climbing (G) times were recorded. *p < 0.05; **p < 0.01 for drugs compared to the vehicle-treated group (n ¼ 10e12 animals/group).
J.-P. Guilloux et al. / Neuropharmacology 73 (2013) 147e159 151treatment (Fig. 4C: p < 0.01 using a KaplaneMeier survival
analysis followed by a ManteleCox log-rank test, conﬁrmed by
one-way ANOVA in Fig. 4D: p < 0.05). Fluoxetine, 18 mg/kg per
day and test 24 h after the last dose, administered for 14 or 21
days failed to reduce the latency to eat signiﬁcantly (p ¼ 0.22 and
p ¼ 0.90 respectively). This lack of effect after 21 days of treat-
ment has been previously observed (David et al., 2009), while
longer duration of treatment induced reduction in latency in the
NSF (Santarelli et al., 2003; Wang et al., 2008). Food consumption
in the home cage was monitored after the behavioural tests and
no effect of vortioxetine on food consumption was observed after
both 14 and 21 days of treatment (Supplementary Fig. 6AeB and
Supplementary Table 1).3.4. Effect of chronic (21 days) vortioxetine on the various steps of
adult hippocampal neurogenesis in 129Sv mice
Vortioxetine, 5 mg/kg per day and assessment 24 h after the
last dose, signiﬁcantly increased the number of BrdUþ cells in the
dentate gyrus of the hippocampus (Fig. 5A p < 0.05 for vortiox-
etine 5 mg/kg per day, unpaired t-test planned comparison;
Supplementary Fig. 7). Furthermore, the same dosing regimen also
increased the survival of newborn neurons (Fig. 5B p < 0.05 for
vortioxetine 5 mg/kg, unpaired t-test planned comparison;
Supplementary Fig. 8), an effect also seen with ﬂuoxetine (18 mg/
kg per day and assessment 24 h after the last dose) (p < 0.05,
following PLSD post-hoc analysis). While the number of
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ments (Fig. 5C, G), chronic vortioxetine (5 and 20 mg/kg per day)
or ﬂuoxetine increased the number of DCXþ cells with tertiary
dendrites (Fig. 5D: F3,19 ¼ 3.3, p < 0.05 for ﬂuoxetine and vorti-
oxetine 5 and 20 mg/kg per day) and the maturation index
(Fig. 5E: F3,19 ¼ 5.5, p < 0.05 for ﬂuoxetine and vortioxetine 5 mg/
kg per day; p < 0.0001 for vortioxetine 20 mg/kg per day). The
behavioural measurements in the NSF correlated with maturation
and branching of neurons in the adult hippocampus across all
drug-treated animals (R ¼ 0.44, p < 0.05).
In line with the signiﬁcant effect of vortioxetine 20 mg/kg per
day in the NSF test after 14 days of treatment (Fig. 4A), this dosing
regimen also had an effect on some stages of neurogenesis.
Compared to 21 days of treatment, the number of doublecortin-
positive cells was unchanged (Fig. 6A, p > 0.05 for all treatment;
Supplementary Fig. 9), but the number of DCXþ cells with tertiary
dendrites was signiﬁcantly increased (Fig. 6B: p < 0.05 for vorti-
oxetine 20 mg/kg per day, unpaired t-test, planned comparison), as
was the maturation index (Fig. 6C: p < 0.05 for vortioxetine 20 mg/
kg per day, unpaired t-test planned comparison). After 21 days,
behavioural measurements in the NSF were correlated with
maturation and branching of neurons in the adult hippocampus
across all drug-treated animals (R ¼ 0.70, p < 0.01).
To further examine the effects of treatment on the dendritic
morphology of newborn cells, we performed Sholl analyses on
DCXþ cells with tertiary dendrites (Fig. 6E). In the groups treated
chronically with vortioxetine or ﬂuoxetine, DCXþ cells displayed
increased dendritic length (Fig. 6E: F3,12 ¼ 19.1, p < 0.001,
p < 0.0001 for vortioxetine 20 mg/kg per day and p < 0.05 for
ﬂuoxetine) and increased number of intersections (Fig. 6F:
F3,12 ¼ 17.3, p < 0.001, p < 0.0001 for vortioxetine 20 mg/kg per day
and p < 0.01 for ﬂuoxetine).4. Discussion
In this study performed in two different strains of mice, and
using various behavioural test associated with emotion-related
disorders and/or antidepressant treatment response, we found
converging evidence for anxiolytic and antidepressant effects of
vortioxetine, a novel antidepressant with multimodal activity, in
preclinical models.
4.1. Behavioural effects of vortioxetine
4.1.1. Acute antidepressant/anxiolytic activity
An acute dose of vortioxetine corresponding to 60e70% occu-
pancy of the SERT and >90% 5-HT3 receptor occupancy decreased
spontaneous (OF) and novelty-related (NSF) anxiety in naïve BALB/
cJ and 129Sv mice, respectively, to the same extent as the benzo-
diazepine, diazepam. In line with previous observations, an acute
dose of the SSRI, ﬂuoxetine, was inactive at a dose corresponding to
>90% SERT occupancy (Holmes and Rodgers, 2003). These obser-
vations support the hypothesis that the acute anxiolytic activity of
vortioxetine is mediated by a mechanism that does not only rely on
occupancy of the SERT. This is in line with the ﬁnding that vorti-
oxetine has antidepressant effects in patients at doses where only
approximately 50% of the SERT are occupied as shown in PET im-
aging studies (Areberg et al., 2012).
In both animal models, the anxiolytic effects of vortioxetine
were not statistically signiﬁcant at the highest dose (10 mg/kg)
tested. This biphasic doseeresponse relation was not observed in
previously reported acute studies in rat and mouse models of
anxiety and depression, i.e., rat social interaction (signiﬁcant ef-
fect at 2, 4 and 8 mg/kg, p.o., corresponding to up to 50% SERT
occupancy), rat conditioned fear (signiﬁcant effect at 3.9 and
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Fig. 3. Effects of chronic vortioxetine treatment in the open ﬁeld paradigm and the forced swim test in BALB/cJ@Rj mice. Behavioural effects of vortioxetine were studied after 21
days of administration at doses of 5 and 20 mg/kg/day, compared to those of vehicle and ﬂuoxetine (18 mg/kg/day) in the open-ﬁeld paradigm or the mouse forced swim test. Data
are expressed as mean  SEM. Anxiety was expressed as total of the time spent in the centre (A) and the number of entries in the centre (B) for the entire session. Locomotor activity
was reported as total ambulatory distance travelled in the centre (C) and in the periphery (D) for the entire session. In the FST, mobility (E), swimming (F) and climbing (G) times
were recorded. *p < 0.05; **p < 0.01 for drugs compared to the vehicle-treated group (n ¼ 10e12 animals/group).
J.-P. Guilloux et al. / Neuropharmacology 73 (2013) 147e159 1537.9 mg/kg, s.c., corresponding to approximately 50 and 90% SERT
occupancy) (Mork et al., 2012) and in an unpublished marble
burying study in CD-1 mice (signiﬁcant effects at 3.9 and 7.9 mg/
kg, s.c.) (Sanchez, unpublished data). The underlying mechanism
of the consistent biphasic dose response observed in BALB/cJ and
129Sv mice in the different models is not readily explained.
Indeed, the mechanism of action of vortioxetine is complex,
involving modulation of 5-HT receptors and SERT activity,
resulting in modulation of several neurotransmitter systems
(Mork et al., 2012; Pehrson et al., 2012). Interestingly, 5-HT7 re-
ceptor antagonists have shown a biphasic-response in several
anxiety paradigms (Wesolowska et al., 2006a, 2006b), while 5-
HT3 receptor blockade and 5-HT1A receptor activation may be
involved in dose-dependent anxiolytic effects (Zhang et al., 2001;
Barrett and Gleeson, 1991). Moreover, signiﬁcant strain differ-
ences have been described with respect to stress sensitivity,
neurotransmitter tone and responses to antidepressants; e.g.,BALB/cJ and 129Sv mice were responsive to ﬂuoxetine, whereas
CD-1 and NIH-Swiss mice were not (Lucki et al., 2001). Thus,
complex and oppositely directed interactions between neuro-
transmitter systems and receptor mechanisms may be involved in
the net effects of vortioxetine.
In the FST, a paradigm designed for screening of potential
antidepressants (Rainer et al., 2012; Petit-Demouliere et al.,
2005) an acute dose (5 mg/kg, p.o.) of vortioxetine correspond-
ing to 60e70% SERT occupancy and >90% 5-HT3 receptor occu-
pancy showed an antidepressant-like activity in BALB/cJ mice.
However, while similar SERT and 5-HT3 occupancy was observed
after vortioxetine at both doses tested, only the lowest dose
(5 mg/kg) induced a statistically signiﬁcant antidepressant effect
in the FST. Fluoxetine, as well as the highest dose of vortioxetine
increased the mobility only at the trend level (p < 0.07 and
p < 0.09 respectively). An antidepressant-like effect was also
observed in NIH-Swiss mice (signiﬁcant effect at 15.9 mg/kg, s.c.)
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J.-P. Guilloux et al. / Neuropharmacology 73 (2013) 147e159154(Sanchez, unpublished data). Here, vortioxetine increases both
climbing and swimming behaviour, effects related to increases in
noradrenergic and serotonergic neurotransmissions, respectively,
whereas ﬂuoxetine (>90% SERT occupancy) only affected swim-
ming behaviour. These results corroborate microdialysis experi-
ments showing increases of both neurotransmitters after
vortioxetine administration in rats (Mork et al., 2012). In that
study, immobility was signiﬁcantly reduced by acute treatment
with 7.8 mg/kg vortioxetine, corresponding to z90% SERT occu-
pancy. However, Mork and colleagues observed no speciﬁc effects
of vortioxetine on swimming and climbing parameters in the
Flinders Sensitive Line (FSL) rat model that was used in their
study. This discrepancy with our results may be due to the model
selected. Indeed, this line, selectively bred for high sensitivity to
cholinergic agonism, also display changes in neurotransmitter
systems, speciﬁcally a lower density of 5-HT1A receptors and a
higher density of 5-HT1B receptors in several brain regions (Nishi
et al., 2009; Wegener et al., 2011). While the low afﬁnity of
vortioxetine for rodent 5-HT1A receptors is unlikely to explain the
discrepancy between the ﬁndings of the present study in mice
and the ﬁndings in FSL rats, its partial agonistic action at 5-HT1B
receptors may limit the increase in mobility in the FST, i.e., in a
model of elevated 5-HT levels, a 5-HT1B receptor partial agonistic
effect may block effects on mobility, as observed in other studies
(Gardier et al., 2001; Guilloux et al., 2006, 2011).4.1.2. Chronic antidepressant/anxiolytic activity
Repeated daily dosing of vortioxetine (5 mg/kg, p.o.) for 14 days
or 21 days in 129Sv and 21 days in BALB/cJ mice resulted in
antidepressant/anxiolytic-like effects. Indeed, anxiolytic and/or
antidepressant-like effect was observed in the in the OF paradigm,
the NSF test and the FST, whereas the same dosing regimen with
ﬂuoxetine (18 mg/kg, p.o.) was inactive. As in the acute studies, a
biphasic dose response was observed, as vortioxetine 20 mg/kg per
day was not active.
The behavioural testing took place 24 h after the last dose, at
which time ﬂuoxetine had >90% SERT occupancy, while vortiox-
etine had comparatively low occupancies at SERT and 5-HT3 re-
ceptors. Vortioxetine’s low occupancies 24 h after the ﬁnal chronic
dose can be explained by its half-life. Indeed, experiments per-
formed in rats showed that the half-life of ﬂuoxetine and nor-
ﬂuoxetine (a potent SERT inhibitor (Owens et al., 1997) and
ﬂuoxetine’s active metabolite) are about 5 and 15 h, respectively
(Caccia et al., 1990). However, vortioxetine has a half-life around
3.2 h (Mork et al., 2012) and does not have an active metabolite on
its different targets (Areberg et al., 2012).
The lack of antidepressant/anxiolytic effect of ﬂuoxetine after 21
days dosing is compatible with previous experiences in BALB/cJ and
129SVeV strains, where 28 days of ﬂuoxetine treatment are needed
to achieve an effect (Wang et al., 2008; Dulawa et al., 2004).
Furthermore, in contrast to benzodiazepines, the delayed onset of
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J.-P. Guilloux et al. / Neuropharmacology 73 (2013) 147e159 155anxiolytic effect of SSRIs in tests performed in mouse is consistent
with the delayed onset in their clinical anxiolytic efﬁcacy (Bespalov
et al., 2010).
In conclusion, the ﬁndings indicate that the antidepressant ac-
tivity of vortioxetine is mediated by a mechanism different from
that of an SSRI. Overall, these ﬁndings may indicate that vortiox-
etine exerts its sustained antidepressant/anxiolytic activity by a
mechanism that is not related to a constant SERT inhibition over
time. Furthermore, vortioxetine is equally potent in two mouse
strains with different 5-HT tone (Zhang et al., 2004), an effect thathas not been observed with SSRIs (Kulikov et al., 2011; Cervo et al.,
2005). Here, the lack of strain-dependent effects would support the
hypothesis that mechanisms that are independent of 5-HT syn-
thesis or 5-HT tissue content may be involved.
4.2. Neurogenic effects of vortioxetine
Antidepressant action has been putatively associated with
changes in adult hippocampal neurogenesis (Airan et al., 2007;
David et al., 2007, 2009; Santarelli et al., 2003; Wang et al., 2008).
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J.-P. Guilloux et al. / Neuropharmacology 73 (2013) 147e159 157However, not all antidepressant effects are related to neurogenesis
(David et al., 2009) and increased neurogenesis by itself in naïve
animals does not induce antidepressant effects (Sahay et al., 2011).
Thus, neurogenesis-related effects of antidepressants may be
restricted to speciﬁc behaviours or symptoms that remain to be
fully detailed.
Among all stages implicated in neurogenesis, maturation of
young neurons is a crucial step for the functional integration of
young neurons into neural circuits. Studies in rodents have shown
that treatment with classical SSRIs such as ﬂuoxetine and also novel
antidepressants such as agomelatine can promote maturation of
post-mitotic neurons (Rainer et al., 2012; Dagyte et al., 2010;
Soumier et al., 2009; Wang et al., 2008). Here, we report that
chronic vortioxetine (5 mg/kg, p.o. per day for 21 days) not only
signiﬁcantly increased cell proliferation within the hippocampus,
but also increased the survival rate of BrdUþ cells and the number
of DCXþ cells with tertiary dendrites. Fluoxetine (18 mg/kg per day
p.o.) produced a similar effect in spite of its overall lack of effect in
the NSF test. Similarly, in spite of a lack of an overall effect of vor-
tioxetine at 20mg/kg per day for 14 days in the NSF test, therewas a
signiﬁcant increase in the number of DCXþ cells with tertiary
dendrites, dendritic length and the number of dendritic in-
tersections at this early time point. Interestingly, irrespective of
treatment and treatment duration (14 or 21 days), the latency to
feed vs. the number of DCXþ cells with tertiary dendrites were
correlated. To our knowledge, this is the ﬁrst time such a correla-
tion has been observed.
It would be of interest to deﬁne which targets of vortioxetine
contribute most to its neurogenic effect. There is a large body of
evidence, including the present study, indicating that chronic SERT
blockade is responsible for an increase in several steps of neuro-
genesis. Pharmacological stimulation of 5-HT1A receptors increases
cell proliferation, while its blockade induces opposite effects
(Banasr et al., 2004; Klempin et al., 2010; Radley and Jacobs, 2002;
Santarelli et al., 2003). 5-HT1B receptor blockade has no effect on
cell proliferation within the hippocampus, but pharmacological
dissection of auto- vs. hetero-receptors in rats suggests that acti-
vation of the latter may contribute to cell proliferation (Banasr et al.,
2004). Furthermore, activation by 5-HT1A receptor agonists in ro-
dents increased cell survival in a time-dependent manner (Klempin
et al., 2010; Soumier et al., 2010), while its blockade had opposite
effects (Klempin et al., 2010), reinforcing the present results.
Unfortunately, no study has yet observed the effects of chronic
pharmacological blockade or stimulation of 5-HT1B receptors on
cell survival in the hippocampus in adult rodents.
Overall, while its precise mechanism of action remains to be
detailed, vortioxetine produces a robust neurogenic effect that is
compatible with its anxiolytic/antidepressant activity.
4.3. Comments and limitations
Here, we studied the effects of vortioxetine in selected strains of
mice depending on the readout measured. Adult male 129S6/
SvEvTac mice were used for the NSF study because of their sensi-
tivity to chronic antidepressants in this behavioural model
(Santarelli et al., 2003), and because the rate of hippocampal neu-
rogenesis allows for study antidepressant-induced neurogenesis.
Male BALB/cJ mice were used for the FST studies because of their
high sensitivity to chronic antidepressant treatment in these
models (Belzung and Griebel, 2001; Dulawa et al., 2004), and
because 129S6/SvEVTac mice do not behave adequately in this
paradigm.
Furthermore, neurogenesis results may differ depending on the
strain used. Indeed, 2 strains may utilize different cellular and
molecular machinery to mediate the neurogenic and behaviouraleffects of chronic antidepressant treatment, and thus pro-
neurogenic effects of vortioxetine observed here in 129S6/SvEV-
Tac mice may differ in BALB/cJ mice. However, recent reports show
that female mice of the BALB/c and a 129 substrain (129SvJ) are
quite similar onmeasures of basal adult neurogenesis including cell
proliferation, survival, and neuronal differentiation, although the
129SvJ mice show slightly less survival 4 weeks after BrdU injection
(Kempermann et al., 1997).
Interestingly, the 5 mg/kg dose of vortioxetine had a signiﬁcant
impact on animals’ behaviour after 21 days exposure, but not after
14 days, while this was the opposite for the highest dose. One
possible interpretation of these ﬁndings is that development of
tolerance occurred at the highest dose administered. However, this
needs to be conﬁrmed in other strains of mice, or in appropriate
animal models of major depressive disorders.
Indeed, behavioural and neurogenic effects of vortioxetine need
to be conﬁrmed in other model. For instance, a putative effect of
vortioxetine after stress (unpredictable chronic mild stress [UCMS],
social defeat) or neuroendocrine-induced alterations of animal
behaviour should be assessed, since thesemodels have shown good
predictive validity. Furthermore, studies in genetic models lacking
one or more of the targets involved in vortioxetine’s mechanism of
action would help to dissect the contributions of the individual
targets to the overall effects.
5. Conclusion
Vortioxetine displays a sustained antidepressant and anxiolytic
proﬁle associated with increased neurogenesis at several stages.
The effect of vortioxetine was not associated with SERT occupancy,
suggesting that its mechanism of action is different from that of an
SSRI.
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